	US 12,083,122 B2
	Laureth-4 containing topical formulations
David W. Osborne, Fort Collins, CO (US)
Assigned to ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US)
Filed by ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US)
Filed on Jun. 29, 2023, as Appl. No. 18/216,089.
Application 18/216,089 is a continuation of application No. 17/443,699, filed on Jul. 27, 2021, granted, now 11,730,740.
Claims priority of provisional application 63/057,503, filed on Jul. 28, 2020.
Prior Publication US 2023/0338383 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/5377 (2006.01); A61K 31/573 (2006.01); A61K 38/13 (2006.01); A61K 47/10 (2017.01); A61K 47/20 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0014 (2013.01); A61K 9/08 (2013.01); A61K 31/5377 (2013.01); A61K 31/573 (2013.01); A61K 38/13 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01)]

14 Claims

1. A method for preparing a topical pharmaceutical composition comprising:

combining SHR0302, water, and at least one solvent with laureth-4, wherein the topical pharmaceutical composition does not contain an additional active ingredient.